Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan)
10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF). The main study
objective is to demonstrate that macitentan positively affects the forced vital capacity
(FVC) in comparison with placebo in patients with idiopathic pulmonary fibrosis (IPF).
The secondary objectives are to evaluate the effect of macitentan on the time to disease
worsening or death in patients with IPF, and to evaluate the benefit/risk profile of
macitentan in the treatment of patients with IPF.